deltatrials
Recruiting PHASE2 INTERVENTIONAL 3-arm NCT02727803

Personalized NK Cell Therapy in CBT

Sponsor: M.D. Anderson Cancer Center

Conditions Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Acute Biphenotypic Leukemia Acute Lymphoblastic Leukemia Acute Lymphoblastic Leukemia in Remission Acute Myeloid Leukemia With Myelodysplasia-Related Changes Acute Myeloid Leukemia With Variant MLL Translocations B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 Chemotherapy-Related Leukemia Chronic Myelomonocytic Leukemia Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements ISS Stage II Plasma Cell Myeloma ISS Stage III Plasma Cell Myeloma Myelodysplastic Syndrome Myelodysplastic Syndrome With Excess Blasts Myelodysplastic Syndrome With Gene Mutation Myelodysplastic/Myeloproliferative Neoplasm Previously Treated Myelodysplastic Syndrome Recurrent Acute Myeloid Leukemia Recurrent Adult Acute Myeloid Leukemia Recurrent Hodgkin Lymphoma Recurrent Non-Hodgkin Lymphoma Refractory Acute Lymphoblastic Leukemia Refractory Adult Acute Lymphoblastic Leukemia Secondary Acute Myeloid Leukemia Therapy-Related Myelodysplastic Syndrome
Interventions Allogeneic Natural Killer Cell Line NK-92 Anti-Thymocyte Globulin Busulfan Clofarabine Cyclophosphamide Fludarabine Phosphate Laboratory Biomarker Analysis Melphalan Rituximab Total-Body Irradiation Umbilical Cord Blood Transplantation
Updated 24 times since 2017 Last updated: Nov 5, 2025 Started: May 19, 2016 Primary completion: May 31, 2027 Completion: May 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02727803, this PHASE2 trial focuses on Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and Acute Biphenotypic Leukemia and remains actively recruiting participants. Sponsored by M.D. Anderson Cancer Center, it has been updated 24 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshot~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Jun 2019 · 11 months · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Jan 2020 · 6 months · monthly snapshot~Jan 2020 – ~Sep 2020 · 8 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jul 2022 · 2 months · monthly snapshot~Jul 2022 – ~Nov 2022 · 4 months · monthly snapshot~Nov 2022 – ~Feb 2023 · 3 months · monthly snapshot~Feb 2023 – ~Oct 2023 · 8 months · monthly snapshot~Oct 2023 – ~Dec 2023 · 2 months · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Jun 2024 · 5 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Jun 2025 · 4 months · monthly snapshot~Jun 2025 – ~Dec 2025 · 6 months · monthly snapshot~Dec 2025 – present · 7 months · monthly snapshot

Change History

24 versions recorded

  1. Dec 2025 — Present [monthly]

    Recruiting PHASE2

  2. Jun 2025 — Dec 2025 [monthly]

    Recruiting PHASE2

  3. Feb 2025 — Jun 2025 [monthly]

    Recruiting PHASE2

  4. Sep 2024 — Feb 2025 [monthly]

    Recruiting PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

▶ Show 19 earlier versions

  1. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  2. Jan 2024 — Jun 2024 [monthly]

    Recruiting PHASE2

  3. Dec 2023 — Jan 2024 [monthly]

    Recruiting PHASE2

  4. Oct 2023 — Dec 2023 [monthly]

    Recruiting PHASE2

  5. Feb 2023 — Oct 2023 [monthly]

    Recruiting PHASE2

  6. Nov 2022 — Feb 2023 [monthly]

    Recruiting PHASE2

  7. Jul 2022 — Nov 2022 [monthly]

    Recruiting PHASE2

  8. May 2022 — Jul 2022 [monthly]

    Recruiting PHASE2

  9. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE2

  10. Jan 2021 — Apr 2022 [monthly]

    Recruiting PHASE2

  11. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  12. Jan 2020 — Sep 2020 [monthly]

    Recruiting PHASE2

  13. Jul 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  14. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE2

  15. Jul 2018 — Jun 2019 [monthly]

    Recruiting PHASE2

  16. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  17. Aug 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  18. Feb 2017 — Aug 2017 [monthly]

    Recruiting PHASE2

  19. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

May 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
  • National Cancer Institute (NCI)
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations